Suppr超能文献

前列腺 SBRT 后局部失败主要发生在 PI-RADS 4 或 5 主导的前列腺内病变中。

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion.

机构信息

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Eur Urol Oncol. 2023 Jun;6(3):275-281. doi: 10.1016/j.euo.2022.02.005. Epub 2022 Mar 17.

Abstract

BACKGROUND

A positive post-treatment prostate biopsy following definitive radiotherapy carries significant prognostic implications.

OBJECTIVE

To determine whether local recurrences after prostate stereotactic body radiation therapy (SBRT) are associated with the presence of and occur more commonly within the region of a PI-RADS 4 or 5 dominant intra-prostatic lesion (DIL) identified on pre-treatment multi-parametric magnetic resonance imaging (MRI).

DESIGN, SETTING, AND PARTICIPANTS: 247 patients with localized prostate cancer treated with SBRT at our institution from 2009-2018 underwent post-treatment biopsies (median time to biopsy: 2.2 years) to evaluate local control.

INTERVENTIONS

Prostate SBRT (median 40 Gy in 5 fractions).

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

MRIs were read by a single diagnostic radiologist blinded to other patient characteristics and treatment outcomes. The DIL presence, size, location, and extent were then analyzed to determine associations with the post-treatment biopsy outcomes.

RESULTS AND LIMITATIONS

Among patients who underwent post-treatment biopsies, 39/247 (15.8%) were positive for Gleason-gradable prostate adenocarcinoma, of which 35/39 (90%) had a DIL initially present and 29/39 (74.4%) had a positive biopsy within the DIL. Factors independently associated with post-treatment biopsy outcomes included the presence of a DIL (OR 6.95; p = 0.001), radiographic T3 disease (OR 5.23, p < 0.001), SBRT dose ≥40 Gy (OR 0.26, p = 0.003), and use of androgen deprivation therapy (ADT; OR 0.28, p = 0.027). Among patients with a DIL (N = 149), the only factors associated with post-treatment biopsy outcomes included ≥50% percent cores positive (OR 2.4, p = 0.037), radiographic T3 disease (OR 4.04, p = 0.001), SBRT dose ≥40 Gy (OR 0.22, p < 0.001), and use of ADT (OR 0.21, p = 0.014).

CONCLUSIONS

Our results suggest that men with PI-RADS 4 or 5 DILs have a higher risk of local recurrence after prostate SBRT and that most recurrences are located within the DIL.

PATIENT SUMMARY

We found the presence of a dominant tumor on pre-treatment MRI was strongly associated with residual cancer within the prostate after SBRT and that most recurrences were within the dominant tumor.

摘要

背景

根治性放疗后前列腺活检呈阳性具有重要的预后意义。

目的

确定前列腺立体定向体部放疗(SBRT)后局部复发是否与治疗前多参数磁共振成像(MRI)上识别的 PI-RADS 4 或 5 主导性前列腺内病变(DIL)的存在有关,以及这些病变是否更常见于 DIL 区域。

设计、地点和参与者:2009 年至 2018 年在我们机构接受 SBRT 治疗的 247 例局限性前列腺癌患者接受了治疗后活检(中位活检时间:2.2 年)以评估局部控制情况。

干预措施

前列腺 SBRT(中位 40 Gy,5 个分数)。

测量和统计分析

由一名对其他患者特征和治疗结果不知情的诊断放射科医生对 MRI 进行阅读。然后分析 DIL 的存在、大小、位置和范围,以确定与治疗后活检结果的关系。

结果和局限性

在接受治疗后活检的患者中,39/247(15.8%)前列腺腺癌 Gleason 分级阳性,其中 35/39(90%)最初存在 DIL,29/39(74.4%)活检阳性位于 DIL 内。与治疗后活检结果独立相关的因素包括 DIL 的存在(OR 6.95;p=0.001)、影像学 T3 疾病(OR 5.23,p<0.001)、SBRT 剂量≥40 Gy(OR 0.26,p=0.003)和雄激素剥夺治疗(ADT;OR 0.28,p=0.027)的使用。在存在 DIL 的患者中(N=149),与治疗后活检结果相关的唯一因素包括≥50%的核心阳性(OR 2.4,p=0.037)、影像学 T3 疾病(OR 4.04,p=0.001)、SBRT 剂量≥40 Gy(OR 0.22,p<0.001)和 ADT 的使用(OR 0.21,p=0.014)。

结论

我们的结果表明,PI-RADS 4 或 5 DIL 患者在接受前列腺 SBRT 后发生局部复发的风险较高,并且大多数复发位于 DIL 内。

患者总结

我们发现治疗前 MRI 上存在主导性肿瘤与 SBRT 后前列腺内残留癌症密切相关,并且大多数复发都位于主导性肿瘤内。

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验